The Aryl Ring Or Aryl Ring System Is Bonded Directly To Another Ring Or Ring System Patents (Class 514/650)
  • Patent number: 10350182
    Abstract: The present invention relates to methods of treating overactive bladder and the symptoms associated therewith, for example, urinary urgency, frequency of micturitions, nocturia, and urgency urinary incontinence. One treatment method according to the present invention comprises treatment with the beta-3 adrenergic receptor agonist solabegron. Another treatment combination according to the invention comprises solabegron, and a muscarinic receptor antagonist which results in a synergistic effect on the symptoms associated with OAB.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: July 16, 2019
    Assignee: VELICEPT THERAPEUTICS, INC.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Patent number: 9987322
    Abstract: Methods are provided for relieving pain associated with peripheral neuropathy, by topical application to human skin of a topical composition comprising Hamelia patens extract in combination with a dermatologically-acceptable carrier. According to methods of the invention, the topical composition is applied to human skin at a sufficient concentration and for a sufficient time to relieve pain associated with peripheral neuropathy.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: June 5, 2018
    Inventor: Don Wayne Berry
  • Patent number: 9822301
    Abstract: The present invention provides a compound represented by general formula (1) as well as a liquid crystal composition containing this compound and a liquid crystal display using this liquid crystal composition. Using the compound represented by general formula (1) as a component of a liquid crystal composition makes it possible to obtain a liquid crystal composition having a low viscosity (?), a high ?n, suitable T-i, high miscibility with other liquid crystal compounds, and presenting a liquid crystal phase over a wide temperature range. This is therefore extremely useful as a structural component of a liquid crystal composition for a liquid crystal display requiring a high speed response.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: November 21, 2017
    Assignee: DIC CORPORATION
    Inventors: Kenta Tojo, Takashi Matsumoto
  • Patent number: 9381170
    Abstract: The invention is directed to the use of a compound of formula I as defined herein, a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing a compound of formula I, in treating a mammal, including a human, for a psychiatric disorder or condition selected from the group consisting of stroke, Huntington's disease and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: July 5, 2016
    Assignee: MediSynergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard
  • Patent number: 9345673
    Abstract: The invention is directed to a method of treatment of a cancer, in a mammal, the method comprising administering to said mammal in need of such treatment an effective amount of a cell growth inhibitory compound of formula I or a pharmaceutically acceptable salt form thereof.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: May 24, 2016
    Assignee: MediSynergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard
  • Patent number: 9283196
    Abstract: The invention is directed to the use of a compound of formula I as defined herein, a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing a compound of formula I, in treating a mammal, including a human, for a psychiatric disorder or condition selected from the group consisting of depression, mood disorders, anxiety, schizophrenia, bipolar disorder (also referred to as manic-depressive disorder), addiction, cognitive impairment, Parkinson's and Alzheimer's diseases.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: March 15, 2016
    Assignee: MediSynergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard
  • Patent number: 9126891
    Abstract: The invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by administration of the compound, the method comprising administering to a mammal, especially a human, in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting Human African Trypanosomiasis (HAT), Chagas Disease, Malaria, Leishmaniasis, and other infectious diseases transmitted to humans and animals by exposure to parasites, the method comprising administering to a human or mammal in need of such treatment a compound of formula I as described above.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: September 8, 2015
    Assignee: MediSynergics, LLC
    Inventors: Dennis Michael Godek, Harry Ralph Howard
  • Patent number: 9125900
    Abstract: This invention relates to a pharmaceutical composition for mammals and, more particularly, to a pharmaceutical composition which enhances the action of an anaesthetic used in both human and veterinary applications, which, at least partly, reduces the risk of respiratory depression and enhances pulmonary perfusion. The pharmaceutical composition is characterized in that it contains a serotonergic ligand or any pharmacologically acceptable salt or ester thereof which acts on at least one member of the 5-HT family of serotonergic receptors, preferably on one or more of the 5-HTiA, 5-HT4 and 5-HT7 serotonergic receptors. In an example the ligand is the 8-OH-DPAT ligand. The composition can be used in conjunction with or include an anaesthetic, preferably an opioid anaesthetic, to induce a state of anaesthesia in mammals and it can be used to immobilize wile or non-domestic mammals.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: September 8, 2015
    Assignee: University of the Witwatersrand, Johannesburg
    Inventor: Leith Carl Rodney Meyer
  • Patent number: 9034927
    Abstract: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, reduce biofilms, and/or inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: May 19, 2015
    Assignees: CURZA GLOBAL, LLC, UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Dustin Williams, Ryan Looper, Sujeevini Jeyapalina, Travis Haussener, Paul R. Sebahar, Hari Kanna Reddy
  • Patent number: 8987291
    Abstract: The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: March 24, 2015
    Assignee: Upsher Smith Laboratories, Inc.
    Inventors: Kenneth L. Evenstad, Christian F. Wertz, James S. Jensen, Victoria Ann O'Neill, Stephen M. Berge
  • Patent number: 8987262
    Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: March 24, 2015
    Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de Bordeaux
    Inventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
  • Publication number: 20150080438
    Abstract: The invention relates to selective oestrogen receptor modulators (SERMs) and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception.
    Type: Application
    Filed: December 4, 2012
    Publication date: March 19, 2015
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Tim Wintermantel, Carsten Moeller, Ulrich Bothe, Reinhard Nubbemeyer, Ludwig Zorn, Antonius Ter Laak, Rolf Bohlmann, Lars Wortmann
  • Patent number: 8969417
    Abstract: Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release.
    Type: Grant
    Filed: June 7, 2009
    Date of Patent: March 3, 2015
    Assignee: Pharmatwob Ltd.
    Inventors: Itschak Lamensdorf, Yoram Sela
  • Publication number: 20150057240
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Application
    Filed: February 8, 2013
    Publication date: February 26, 2015
    Inventors: Brian S. J. Blagg, Bhaskar Reddy Kusuma, Teather Sundstrom
  • Publication number: 20150038590
    Abstract: The present invention relates to fungicidal N-cycloalkyl-N-[(cycloalkenylphenyl)methylene]carboxamide derivatives and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.
    Type: Application
    Filed: March 25, 2013
    Publication date: February 5, 2015
    Inventors: Jurgen Benting, Philippe Desbordes, Pierre Cristau, Christophe Dubost, Mazen Es-Sayed, Stephanie Gary, Helene Lachaise, Philippe Rinolfi, Jan-Peter Schmidt, Tomoki Tsuchiya, Jean-Pierre Vors, Ulrike Wachendorff-Neumann
  • Publication number: 20150031738
    Abstract: The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.
    Type: Application
    Filed: December 10, 2012
    Publication date: January 29, 2015
    Applicant: University of Massachusetts
    Inventors: Yan Li, Hitest Thaker, Gregory N. Tew, Dahui Liu, Wenxi Pan
  • Publication number: 20150011559
    Abstract: The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a compound of formula I: wherein A, B, and X have any of the meanings defined in the specification; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 8, 2015
    Inventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Yongzheng Zhang, Malvika Kaul
  • Publication number: 20140370120
    Abstract: The present invention relates to methods of maintaining, and methods of restoring, a desired calcium homeostasis in a non-human terrestrial animal by administering an effective amount of one or more Calcium-Sensing Receptor modulators (CaSRs) to the animal. The invention further provides methods of reducing foot lesions in chickens. The invention also relates to food compositions useful in the methods of the invention.
    Type: Application
    Filed: January 6, 2014
    Publication date: December 18, 2014
    Applicant: MariCal, Inc.
    Inventors: H. William Harris, JR., Marlies Betka, Chris Frederick Holm, Steven Harold Jury
  • Patent number: 8877975
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: November 4, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campbell
  • Publication number: 20140308317
    Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, malaria, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; killing or inhibiting the growth of a Plasmodium species; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.
    Type: Application
    Filed: December 9, 2013
    Publication date: October 16, 2014
    Applicant: CELLCEUTIX CORPORATION
    Inventors: Xiaodong Fan, Yongjiang Xu, Dahui Liu, Michael J. Costanzo
  • Publication number: 20140302131
    Abstract: The present invention discloses a tablet or a capsule for oral administration comprising 0.5-0% (w/w) hyaluronic acid or a salt thereof, an active pharmaceutical ingredient (API), and a coating.
    Type: Application
    Filed: August 31, 2012
    Publication date: October 9, 2014
    Applicant: Novozymes A/S
    Inventor: Ole Moeller Dall
  • Patent number: 8853278
    Abstract: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, reduce biofilms, and/or inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: October 7, 2014
    Assignees: Curza Global, LLC, University of Utah Research Foundation
    Inventors: Ryan Looper, Dustin Williams, Sujeevini Jeyapalina, Travis Haussener, Paul R. Sebahar, Hari Kanna Reddy
  • Publication number: 20140294954
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to create a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8840923
    Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 23, 2014
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
  • Publication number: 20140187557
    Abstract: The present invention relates to a compound of formula (I) including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof; provided that the compound is other than or a pharmaceutically acceptable salt thereof. The claimed compounds are useful for the treatment of a disease, the treatment of which is affected, mediated or facilitated by activating the GHS1A-r receptor. The invention also relates to pharmaceutical compositions thereof and processes for the preparation thereof.
    Type: Application
    Filed: March 10, 2014
    Publication date: July 3, 2014
    Applicant: Janssen Pharmaceutica NV
    Inventors: Bruno Schoentjes, Alain Philippe Poncelet, Julien Georges Pierre-Olivier Doyon, Joannes Theodorus Maria Linders, Lieven Meerpoel, Luc August Laurentius Ver Donck
  • Patent number: 8754132
    Abstract: Highly selective 5-HT(2C) receptor agonists receptors are disclosed. The 5-HT(2C) receptor agonists are used in the treatments of disease and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: June 17, 2014
    Assignees: The Board of Trustees of the University of Illinois, The University of North Carolina at Chapel Hill
    Inventors: Alan Kozikowski, Bryan Roth, Andreas Svennebring, Sung Jin Cho
  • Publication number: 20140135360
    Abstract: The present invention relates to antimalarial compounds and their use against protozoa of the genus Plasmodium, including drug-resistant Plasmodia strains. This invention further relates to compositions containing such compounds and a process for making the compounds.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 15, 2014
    Applicant: Jacobus Pharmaceutical Company, Inc
    Inventors: Gavin David Heffernan, David Penman Jacobus, Guy Alan Schiehser, Hong-Ming Shieh, Wenyi Zhao
  • Patent number: 8716347
    Abstract: Tramadol or a pharmaceutically acceptable salt thereof is used in the manufacture of a pharmaceutical preparation for the treatment of functional gastrointestinal disorders such as irritable bowel syndrome.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: May 6, 2014
    Assignee: Euro-Celtique S.A.
    Inventor: David Fowler
  • Patent number: 8669291
    Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: March 11, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
  • Patent number: 8546615
    Abstract: The present invention relates to solid racemic dapoxetine, solid dapoxetine S(+)enantiomer, processes for their preparation and their use in the pharmaceutically active compound dapoxetine acid addition salt, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: October 1, 2013
    Assignee: Symed Labs Limited
    Inventors: Dodda Mohan Rao, Pingili Krishnareddy, Aadepu Jithender
  • Publication number: 20130252964
    Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an Aspergillus infection.
    Type: Application
    Filed: January 18, 2013
    Publication date: September 26, 2013
    Applicant: PolyMedix, Inc.
    Inventors: Richard W. Scott, Katie Freeman, Haizhong Tang, Gill Diamond
  • Publication number: 20130252890
    Abstract: The invention relates to selective oestrogen receptor modulators (SERM) and methods of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception.
    Type: Application
    Filed: June 21, 2011
    Publication date: September 26, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Tim Wintermantel, Carsten Möller, Ulrich Bothe, Reinhard Nubbemeyer, Ludwig Zorn, Dirk Kosemund, Antonius Ter Laak, Rolf Bohlmann, Lars Wortmann, Donald Bierer
  • Patent number: 8507525
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: August 13, 2013
    Assignee: Auris Medical AG
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Patent number: 8461146
    Abstract: The present invention provides an oral pharmaceutical composition for the treatment of premature ejaculation, and the composition provides the effective and excellent treatment of premature ejaculation as well as reduced side effects like nausea, vomiting, drowsiness, sedation effect, awakening effect, and weight-loss etc.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: June 11, 2013
    Assignees: Yuhan Corporation, Hyun Uk SEOL
    Inventors: Hyun Uk Seol, Young Sung Lee, Young Hun Kim, Kyeong Bae Kim, Jeong Min Seo, Kyoung Kyu Ahn
  • Publication number: 20130123293
    Abstract: The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).
    Type: Application
    Filed: December 14, 2012
    Publication date: May 16, 2013
    Applicant: UPSHER-SMITH LABORATORIES, INC.
    Inventor: UPSHER-SMITH LABORATORIES, INC.
  • Publication number: 20130109713
    Abstract: The invention provides a compound of formula I:or a salt thereof, wherein R3-R8 and X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 2, 2013
    Inventors: Edmond J. Lavoie, Ajit Parhi, Daniel S. Pilch
  • Patent number: 8420691
    Abstract: Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: April 16, 2013
    Assignee: Gruenenthal GmbH
    Inventors: Klaus Schiene, Guenter Haase, Babette-Yvonne Koegel, Elmar Friderichs, Ulrich Jahnel
  • Patent number: 8404749
    Abstract: A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amount of a (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol compound or a physiologically acceptable salt thereof, such as the hydrochloride or citrate salt.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: March 26, 2013
    Assignee: Gruenenthal GmbH
    Inventors: Klaus Schiene, Guenter Haase, Babette-Yvonne Koegel, Elmar Friderichs, Ulrich Jahnel
  • Patent number: 8383682
    Abstract: A composition comprises surface-modified nanoparticles of at least one amphoteric metal oxide or oxyhydroxide. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising (i) at least one surface modifier selected from lactate, thiolactate, and mixtures thereof, and (ii) at least one surface modifier selected from halide, nitrate, acetate, carbonate, formate, propionate, sulfate, bromate, perchlorate, tribromoacetate, trichloroacetate, trifluoroacetate, carboxylate comprising from one to about four alkyleneoxy moieties, chlorate, and mixtures thereof.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: February 26, 2013
    Assignee: 3M Innovative Properties Company
    Inventor: Timothy D. Dunbar
  • Patent number: 8354454
    Abstract: The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: January 15, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sander G. Mills, Amjad Ali, Cameron Smith
  • Patent number: 8334308
    Abstract: The present invention relates to biphenyl-based renin inhibitor compounds having amino-terminal groups, and their use in treating cardiovascular events and renal insufficiency.
    Type: Grant
    Filed: August 18, 2008
    Date of Patent: December 18, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Helene Juteau, Michel Gallant, Daniel Dube, Patrick Roy, Renee Aspiotis, Rejean Fortin, Patrick Lacombe, Daniel McKay, Tom Yao-Hsiang Wu
  • Patent number: 8227643
    Abstract: This invention relates to bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable salts and their use in the modulation of Sirtuin 1 (Sirt1) and there use in neuroprotection for subject suffering from neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease, including Parkinson's plus diseases such as multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and dementia with Lewy bodies, and in the manufacture of medicaments for such Sirt1 modulation and neuroprotection.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: July 24, 2012
    Assignee: ProteoTech, Inc.
    Inventors: Alan D. Snow, Qubai Hu, Judy A. Cam
  • Publication number: 20120130147
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, and q have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 24, 2012
    Inventors: Dirk FINSINGER, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Kai Schiemann, Wolfgang Staehle, Christiane Amendt, Nina Heiss, Frank Zenke
  • Publication number: 20120129942
    Abstract: A stable antifungal composition for topical application on a nail comprising a diol component, an organic acid component, a volatile vehicle, an antifungal agent and a keratolytic agent; the active compound and the keratolytic agent are soluble in the composition in the absence of said volatile vehicle, and wherein at least one in the group selected from the antifungal agent and the keratolytic agent is present in solid state in the composition in the presence of said volatile vehicle. Preferred ingredients include propylene glycol, lactic acid, ethyl acetate, urea and terbinafine or naftifine.
    Type: Application
    Filed: August 13, 2010
    Publication date: May 24, 2012
    Applicant: MOBERG DERMA AB
    Inventor: Ake Lindahl
  • Publication number: 20120093929
    Abstract: The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.
    Type: Application
    Filed: May 5, 2009
    Publication date: April 19, 2012
    Applicant: Euro-Celtique S.A.
    Inventors: Alexander Oksche, Kevin J. Smith, Derek Prater, Malcolm Walden, Will Heath, Bernard Kennedy, Vanessa Addison, Hassan Mohammad
  • Patent number: 8138226
    Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: March 20, 2012
    Assignee: Auspex Pharmaceuticals
    Inventors: Thomas G. Gant, Sepehr Sarshar
  • Patent number: 8101666
    Abstract: The invention provides methods for detection of medical disorders, associated with cellular oxidative stress, cell degeneration and/or cell death. The invention further relates to compounds comprising a thiol (—SH) group, for detecting cells undergoing oxidative stress, degeneration and/or a death process. The invention further provides methods for utilizing the compounds in medical practice, for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: January 24, 2012
    Assignee: Aposense Ltd.
    Inventors: Ilan Ziv, Anat Shirvan
  • Patent number: 8093299
    Abstract: The present invention relates to methods for treating bowel disorders using calcimimetics.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: January 10, 2012
    Assignees: Amgen Inc., Yale University
    Inventors: John Peter Geibel, Steven Charles Hebert, Patricia Hebert, legal representative, David Martin, Deborah A. Russell
  • Publication number: 20110301244
    Abstract: The present invention relates to pharmaceutical compositions containing Naratriptan, a compound selected from the group consisting of 2-HPOD, 2-HPHM, 4-PPED, 4-BPED and 2-PPED, and optionally, a pharmaceutically acceptable excipient.
    Type: Application
    Filed: August 12, 2011
    Publication date: December 8, 2011
    Applicant: Emisphere Technologies, Inc.
    Inventor: David GSCHNEIDNER
  • Publication number: 20110287094
    Abstract: The invention provides a delivery device for the delayed release of an active agent in the gastrointestinal tract comprising a core, comprising an active agent; a first outer coating, comprising a relatively hydrophobic substantially water insoluble polymer having substantially water insoluble hydrophilic particles embedded therein; and a first inner coating layer, comprising an agent that can cause the dissolution of at least one of the water insoluble components of the outer coating, and optionally a water soluble polymer, such that the insoluble particles in the outer coating, upon absorption of liquid, form channels leading to the inner coating layer, thus enabling the dissolution thereof, whereby the agents contained therein are released to cause the dissolution and/or degradation (destruction) of the outer coating, and the release of the pharmaceutically acceptable active agent from the core of the device.
    Type: Application
    Filed: August 2, 2011
    Publication date: November 24, 2011
    Inventors: Adel PENHASI, Mila GOMBERG, Maxim GOMBERG